Race Oncology Ltd. (AU:RAC)

ASX:RAC

RAC

Race Oncology Ltd.

RESEARCH TOOLSreports

Want to see AU:RAC full AI Analyst Report?

Race Oncology Ltd. (RAC) Price & Analysis

36 Followers

RAC Stock Chart & Stats

AU$2.70

-AU$0.03(-2.27%)

At close: Jan 09 4:00 PM EST

AU$2.70

-AU$0.03(-2.27%)

Day’s Range― - ―

52-Week RangeAU$1.12 - AU$4.90

Previous CloseN/A

Volume68.10K

Average Volume (3M)373.28K

Market Cap

AU$461.52M

Enterprise ValueAU$475.22M

Total Cash (Recent Filing)AU$20.94M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.46

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding195,559,740

10 Day Avg. Volume310,625

30 Day Avg. Volume373,283

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)12.69

Price to Sales (P/S)33.63

P/FCF Ratio-44.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially reduces refinancing and interest-rate risk for a clinical-stage biotech. This conservatism preserves optionality to fund trials or partnerships, lengthening runway relative to leveraged peers and supporting strategic execution over the next 2–6 months.

Improving FY2025 Margins And LossesNarrowing losses and a very strong gross margin indicate better cost control and higher-quality revenue mix. Sustained margin improvement increases the chance management can extend programs or attract partners, reducing burn per dollar of revenue over the medium term.

Focused Clinical-stage Oncology PipelineA focused pipeline centered on a repurposed oncology asset concentrates scientific and commercial efforts, potentially accelerating development and partnership interest. Specialization can attract collaborators and streamline regulatory strategy, sustaining value-creation potential beyond short-term cycles.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow means the company must rely on external financing or partnerships to fund trials. Continued cash burn pressures strategic flexibility and increases dilution or deal dependence, creating a material execution risk over the coming months.

Revenue VolatilityLarge swings in revenue signal uneven commercialization or lumpy milestone recognition, complicating planning and making runway assessment harder. For a clinical-stage firm, unpredictable revenue undermines the ability to sustainably finance development and weakens partner negotiation leverage.

Ongoing Unprofitability & Falling EquityDeclining equity and persistent negative ROE show shareholder capital is being consumed, limiting internal funding for trials and increasing reliance on external capital. Over 2–6 months this heightens dilution risk and could constrain strategic options if losses persist.

Race Oncology Ltd. News

Racura Raises $24.4m as 97% of Piggyback Options Are Exercised

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology has secured $24.38 million from the...

9d ago

RAC

Racura Oncology Options Lapse, Trimming Potential Equity Dilution

Race Oncology Ltd. ( ($AU:RAC) ) has shared an announcement. Racura Oncology has announced the cessation of 631,201...

9d ago

RAC

Racura Oncology Raises $31.2m as Specialist Investor Takes Strategic Stake

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology has secured a binding commitment from...

9d ago

RAC

Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares

Race Oncology Ltd. ( ($AU:RAC) ) just unveiled an update. Racura Oncology has applied to the ASX for...

12d ago

RAC

Racura Oncology Seeks ASX Quotation for Over 1.1 Million New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology Ltd has applied to the ASX...

15d ago

RAC

Racura Oncology Plans Share Placement to Fund Oncology Programs

Race Oncology Ltd. ( ($AU:RAC) ) has provided an announcement. Racura Oncology Ltd, an ASX-listed biotech company focused...

15d ago

RAC

Racura Oncology underwrites expiring options to secure $25m for cancer trials

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has secured an underwriting...

15d ago

RAC

Racura Oncology director boosts stake with $500,000 option exercise

Race Oncology Ltd. ( ($AU:RAC) ) has shared an update. Racura Oncology director Daniel Tillett has increased his...

16d ago

RAC

Racura Oncology Seeks ASX Quotation for 1.5 Million New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology has applied to the ASX for...

16d ago

RAC

Racura Oncology Director Boosts Stake With $500,000 Option Exercise

Race Oncology Ltd. ( ($AU:RAC) ) has provided an announcement. Racura Oncology has reported a change in the...

18d ago

RAC

RAC FAQ

What was Race Oncology Ltd.’s price range in the past 12 months?

Race Oncology Ltd. lowest share price was AU$1.11 and its highest was AU$4.90 in the past 12 months.

What is Race Oncology Ltd.’s market cap?

Race Oncology Ltd.’s market cap is AU$461.52M.

When is Race Oncology Ltd.’s upcoming earnings report date?

Race Oncology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 81 days.

How were Race Oncology Ltd.’s earnings last quarter?

Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.

Is Race Oncology Ltd. overvalued?

According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Race Oncology Ltd. pay dividends?

Race Oncology Ltd. does not currently pay dividends.

What is Race Oncology Ltd.’s EPS estimate?

Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Race Oncology Ltd. have?

Race Oncology Ltd. has 195,559,740 shares outstanding.

What happened to Race Oncology Ltd.’s price movement after its last earnings report?

Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.

Which hedge fund is a major shareholder of Race Oncology Ltd.?

Currently, no hedge funds are holding shares in AU:RAC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Race Oncology Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-47.44%

Trailing 12-Months

Asset Growth

14.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Race Oncology Ltd.

Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.